Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration

被引:87
作者
Sim-Selley, Laura J.
Schechter, Nicole S.
Rorrer, W. Kirk
Dalton, George D.
Hernandez, Jerry
Martin, Billy R.
Selley, Dana E.
机构
[1] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA 23298 USA
关键词
D O I
10.1124/mol.105.019612
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Long-term cannabinoid administration produces region-dependent CB 1 receptor desensitization and down-regulation. This study examined the time course for normalization of CB 1 receptors and G-protein activation using H-3-labeled N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716A) and guanosine 5'-O-(3-[S-35] thio) triphosphate ([S-35] GTP gamma S binding), respectively, in hippocampus and striatum/globus pallidus (GP). Mice were treated with escalating doses of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) or R(+)-[ 2,3-dihydro-5-methyl-3-[(morpholinyl) methyl] pyrrolo-[ 1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate (WIN55,212-2) for 15 days, and tissue was collected 1, 3, 7, or 14 days after final injection. [H-3] SR141716A and WIN55,212-2-stimulated [S-35] GTP gamma S binding were decreased in both regions 1 day after treatment. WIN55,212-2-stimulated G-protein activation in striatum/GP returned to control level at 3 days after cessation of treatment with either drug but did not return to control level in hippocampus until 14 days. CB 1 receptor binding did not recover to control levels until day 7 or 14 after treatment in striatum/GP and hippocampus, respectively. The mechanism of CB 1 binding site down-regulation was investigated after long-term Delta(9)-THC treatment. Analysis of CB 1 receptor mRNA in hippocampus and striatum/GP showed that transcriptional regulation could not explain prolonged recovery rates from CB 1 receptor down-regulation. In contrast, CB 1 receptor protein, as determined by immunoblot analysis, matched the down-regulation and recovery rates of CB 1 receptor binding sites relatively closely. These data demonstrate that cannabinoid-induced decreases in CB 1 receptor function persist for relatively long time periods after cessation of long-term drug treatment and that CB 1 receptor signaling recovers more quickly in striatum/GP than hippocampus. Moreover, down-regulation of CB 1 receptor binding sites does not seem to result mainly from transcriptional regulation, suggesting that adaptive regulation of CB 1 receptors in brain primarily occurs at the protein level.
引用
收藏
页码:986 / 996
页数:11
相关论文
共 41 条
[1]   CANNABINOID PRECIPITATED WITHDRAWAL BY THE SELECTIVE CANNABINOID RECEPTOR ANTAGONIST, SR 141716A [J].
ACETO, MD ;
SCATES, SM ;
LOWE, JA ;
MARTIN, BR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 282 (1-3) :R1-R2
[2]   Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail [J].
Andersson, H ;
D'Antona, AM ;
Kendall, DA ;
Von Heijne, G ;
Chin, CN .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :570-577
[3]   Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice [J].
Bass, CE ;
Martin, BR .
DRUG AND ALCOHOL DEPENDENCE, 2000, 60 (02) :113-119
[4]   Endocannabinoid signaling in rat somatosensory cortex:: Laminar differences and involvement of specific interneuron types [J].
Bodor, AL ;
Katona, I ;
Nyíri, G ;
Mackie, K ;
Ledent, C ;
Hájos, N ;
Freund, TF .
JOURNAL OF NEUROSCIENCE, 2005, 25 (29) :6845-6856
[5]   Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain [J].
Breivogel, CS ;
Childers, SR ;
Deadwyler, SA ;
Hampson, RE ;
Vogt, LJ ;
Sim-Selley, LJ .
JOURNAL OF NEUROCHEMISTRY, 1999, 73 (06) :2447-2459
[6]   TOLERANCE TO CHRONIC ADMINISTRATION OF CANNABIS SATIVA (MARIHUANA) IN RATS [J].
CARLINI, EA .
PHARMACOLOGY, 1968, 1 (02) :135-&
[7]  
Chan D, 1998, NETW COMPUT, V9, P18
[8]  
Cichewicz DL, 2001, J PHARMACOL EXP THER, V297, P121
[9]  
COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218
[10]  
Coutts AA, 2001, J NEUROSCI, V21, P2425